Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05656183 · ClinicalTrials.gov registry record · NA
CardioSeq: Impact of WGS in Individuals With CVD
A NA study of Cardiovascular Diseases, sponsored by Illumina.
- Active
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 1
- Study location
NCT05656183: Active NA study of Cardiovascular Diseases, sponsored by Illumina.
NCT05656183 is a NA study of Cardiovascular Diseases that is active but no longer recruiting, run by Illumina. The registered enrollment target is 1,500 participants, below the 26,969-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05656183, a NA study of Cardiovascular Diseases, is active but no longer recruiting, sponsored by Illumina.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both within the WGS group and compared to a contemporaneous, matched (2:1) usual care (UC) group sourced from EHR records.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST TruGenome Cardiovascular Disease test
Study Locations (1)
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2023-01-06 |
| Est. Completion | 2025-06 |
| Phase | NA |
What the registry record for NCT05656183 still lists
NCT05656183 is an interventional study that assigns participants to a tested intervention. Its 1,500 participants enrollment target places it among the larger protocols in the corpus, below the 26,969-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which TruGenome Cardiovascular Disease test is the first listed.
NCT05656183 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05656183 about?
NCT05656183 is a clinical study titled "CardioSeq: Impact of WGS in Individuals With CVD". This is a prospective, single-center, open-label study to investigate the diagnostic efficacy of the TruGenome CVD test and its impact on clinical management compared to usual care in individuals with cardiovascular disease. Diagnostic yield and changes of management (CoM) will be assessed both with...
What is the current status of trial NCT05656183?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2023-01-06. Estimated completion is 2025-06.
What conditions does trial NCT05656183 study?
This clinical trial studies the following conditions: Cardiovascular Diseases.
What interventions are being tested in trial NCT05656183?
The interventions under investigation include: TruGenome Cardiovascular Disease test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05656183?
This trial is sponsored by Illumina, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05656183 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05656183's enrollment target sits among peer trials
1,500 44th of 300 higher than 257 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI